Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.76 |
| ▸ | SELP | P16109 | 2/20 | 0.63 |
| ▸ | SELL | P14151 | 1/20 | 0.63 |
| ▸ | MAG | P20916 | 9/20 | 0.62 |
| ▸ | SELE | P16581 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378134 | 1.00 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL29732821 | 1.00 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL30650364 | 0.98 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700276 | 0.98 | SIGLEC7 (0.74) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700681 | 0.97 | SIGLEC7 (0.75) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700314 | 0.97 | SIGLEC7 (0.73) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700344 | 0.97 | SIGLEC7 (0.75) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31179876 | 0.97 | SIGLEC7 (0.73) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700290 | 0.97 | SIGLEC7 (0.75) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700527 | 0.97 | SIGLEC7 (0.73) | SIGLEC7SELPSELLMAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250270319-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-3341411-B1 | ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250145709-A1 | ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-05-08 | — | — | US | disclosed |
| EP-3368575-B1 | ANTI-SIGLEC-9 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12258398-B2 | Anti-Siglec-5 antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-12247073-B2 | Anti-CD33 antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-03-11 | — | — | US | disclosed |
| US-12227568-B2 | Anti-Siglec-7 antibodies and methods of use thereof | ALECTOR LLC (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240329054-A1 | SOLUBLE CD33 AS A BIOMARKER FOR ANTI-CD33 EFFICACY | ALECTOR LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240067723-A1 | ANTI-SIGLEC-9 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11667710-B2 | Anti-Siglec-9 antibodies and methods of use thereof | ALECTOR LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4149625-A2 | TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS | Viratides, LLC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230035072-A1 | METHODS OF USE OF ANTI-CD33 ANTIBODIES | ALECTOR LLC (US) | 2023-02-02 | — | — | US | disclosed |
| US-20220411503-A1 | ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220315656-A1 | ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220251190-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-11390680-B2 | Anti-Siglec-7 antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220162309-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-11254743-B2 | Anti-CD33 antibodies and methods of use thereof | ALECTOR LLC (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | SIGLEC7 692/4885SELP 158/4885SELL 156/4885 |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | SIGLEC7, SIGLEC9, ENGASE | SIGLEC7 1/4885SELP 128/4885SELL 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.